Bio Institute

파이프라인 치료제
Characteristic Project name Expected indicant Developmental phase
Cell-mediated gene therapy Degenerative arthritis phase 3(III)
Gene therapy Anticancer agent Pre-clinical
Gene therapy Pain treatment Pre-clinical
Gene therapy Anticancer agent Pre-clinical

*Relevant project’s details will be displayed if you click the name of the project.

INVOSSA-K® inj

[DETAIL VIEW]

phase 3(III)

KLS-1010

In development of viral vector-mediated delivery of therapeutic substance which induce immune response to cancer antigen

Pre-clinical

KLS-2020

In development of viral vector-mediated delivery of therapeutic gene which has pain relieve effect by blocking pain signal transmission

Pre-clinical

KLS-3020

Development of tumor killing virus which selectively eliminates cancer cells without damaging normal cells, unlike the existing anticancer treatments with severe side effects. KLS-3020 contains genes which have anti-cancer effects into developed viral vector

Pre-clinical